OverviewChartProfileKey statisticsFinancialsNewsTraderScreen

Swedish Orphan Biovitrum AB/  SE0000872095  /

Cboe Europe DXE
3/31/2023  2:37:07 PM Chg. +2.00 Volume Bid3/31/2023 Ask2:37:15 PM Market Capitalization Dividend Y. P/E Ratio
244.80SEK +0.82% 57,850
Turnover: 5.46 mill.		 244.70Bid Size: 558 245.00Ask Size: 190 72.07 bill.SEK 0.00% 22.22
GlobeNewswire 3/28/2022 Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Op...
GlobeNewswire 3/10/2022 Selecta Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Busines...
GlobeNewswire 3/9/2022 Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in hemophilia A, demonst...
GlobeNewswire 1/11/2022 Avalo Therapeutics Appoints Stephen Smolinski as Chief Commercial Officer
GlobeNewswire 12/22/2021 Pharvaris Announces Changes to its Board of Directors
GlobeNewswire 12/15/2021 Apellis and Sobi Announce EU Approval of Aspaveli® (pegcetacoplan) for Treatment of PNH
GlobeNewswire 12/13/2021 Apellis and Sobi Report Empaveli™ (pegcetacoplan) Demonstrated Sustained Normalization of Clinical M...
GlobeNewswire 12/1/2021 Selecta Biosciences and Sobi Announce Completion of Enrollment in DISSOLVE Phase 3 Study Evaluating ...
GlobeNewswire 10/15/2021 Apellis and Sobi Receive Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of PN...
GlobeNewswire 9/7/2021 Nature Medicine publishes positive phase 3 anakinra study results in patients with COVID-19 pneumoni...
GlobeNewswire 7/8/2021 Amolyt Pharma Announces Appointment of Two Directors
GlobeNewswire 5/25/2021 Apellis and Sobi Report Positive Top-line Results from the Phase 3 PRINCE Study of EMPAVELI™ (pegcet...
GlobeNewswire 5/19/2021 DBV Technologies Announces Results of its 2021 Ordinary and Extraordinary General Meeting and the Ap...
GlobeNewswire 3/17/2021 Apellis and Sobi: The New England Journal of Medicine Publishes Phase 3 PEGASUS Study Results Compar...
GlobeNewswire 12/22/2020 FDA Approves KINERET® (anakinra) for the Treatment of Deficiency of IL-1 Receptor Antagonist (DIRA)
GlobeNewswire 12/10/2020 Apellis and Sobi Report Positive Top-line Results at 48 Weeks from the Phase 3 PEGASUS Study of Pegc...
GlobeNewswire 11/19/2020 Apellis and Sobi Announce First Patient Dosed in Potentially Registrational ALS Study of Pegcetacopl...
GlobeNewswire 11/2/2020 Apellis Pharmaceuticals Reports Third Quarter 2020 Financial Results
GlobeNewswire 10/27/2020 Apellis and Sobi Enter Collaboration for Global Co-development and Ex-US Commercialization of System...
GlobeNewswire 9/30/2020 Selecta Biosciences and Sobi Announce Topline Data of SEL-212 from the Phase 2 COMPARE Trial Support...
GlobeNewswire 9/23/2020 First Patient Randomized in the Phase 3 DISSOLVE Clinical Program of SEL-212 for Chronic Refractory ...
GlobeNewswire 9/16/2020 FDA Granted Pediatric Disease Designation for OXi-4503
GlobeNewswire 9/16/2020 FDA Granted Pediatric Disease Designation for OXi-4503
GlobeNewswire 9/8/2020 Selecta Biosciences to Participate in Upcoming Investor Conferences
GlobeNewswire 9/1/2020 Selecta Biosciences Secures Up To $35 Million Debt Financing with Oxford Finance LLC and Silicon Val...